MCL Literature Feed

This review highlights stereotyped B-cell receptors in MCL, suggesting common antigen-driven pathways that could provide a basis for molecular subclassification to refine patient risk stratification.

This methods paper details using sensitive qPCR and ddPCR to detect MRD in B-cell lymphomas by targeting Ig gene rearrangements and chromosomal translocations, relevant for MCL's t(11;14).

For younger MCL patients post-transplant, this phase III analysis shows conditional survival improves over time, especially after R-CHOP, providing data for dynamic prognostication and reinforcing intensive induction.

Mantle cell lymphoma can directly cause retinal vascular occlusion leading to ischemic retinopathy, a rare but vision-threatening extramedullary manifestation that clinicians should recognize.

The Australasian Lymphoma Alliance provides consensus guidelines for MCL diagnosis and management, integrating novel therapies and risk-stratification using biomarkers like TP53, blastoid morphology, and high Ki67.

This review of PROTAC design outlines a novel protein degradation technology with potential to overcome resistance to targeted therapies like BTK inhibitors in mantle cell lymphoma.

This SEER database study on anal lymphomas is not relevant to the MCL field, as it includes only one case of mantle cell lymphoma (1.3% of the cohort).

A simulation model using 20 years of real-world data establishes a baseline for lifetime treatment trajectories, crucial for evaluating the cost-effectiveness of new targeted therapies in MCL.

This study confirms that low/negative CD200 and lower CD43 expression by flow cytometry reliably distinguish MCL from CLL, improving routine diagnostic accuracy for B-cell lymphoproliferative disorders.

This first-in-literature case report identifies sclerosing cholangitis as a novel, severe hepatobiliary toxicity of Tecartus CAR-T therapy in a relapsed/refractory MCL patient, expanding the known safety profile.

This large Swedish real-world study on limited-stage MCL demonstrates that radiotherapy-containing frontline regimens are associated with excellent long-term outcomes, supporting a curative-intent, less-intensive approach for this rare subset.

Bioinformatic analysis reveals a positive correlation between STING expression and cytolytic score in MCL, suggesting STING may be a biomarker for immune activity and a potential immunotherapy target.

This case report highlights the critical role of MRI in diagnosing post-CAR-T neurotoxicity in MCL, demonstrating findings like limbic encephalitis to differentiate ICANS from other CNS pathologies.

The novel agent Ironomycin induces MCL cell death by targeting iron metabolism addiction, identifying a potential new therapeutic strategy based on a metabolic vulnerability.

This case report describes blastoid MCL presenting as an isolated cecal mass, highlighting an unusual clinical presentation and the need to consider lymphoma in the differential for GI tumors.

An MCL patient post-autologous transplant developed persistent COVID-19 with a novel Remdesivir resistance mutation, highlighting the risk of immunocompromised hosts becoming reservoirs for drug-resistant SARS-CoV-2 variants.

This meta-analysis of tirabrutinib monotherapy in relapsed/refractory B-cell lymphomas, including MCL, shows a pooled 72.5% overall response rate with manageable neutropenia and skin-related toxicities.

This case report details persistent cytokine release syndrome in an MCL patient after glofitamab, highlighting a rare, severe toxicity profile requiring vigilant management beyond standard CRS protocols.

This case report identifies a novel jumping translocation of 3q in an MCL patient, linking this rare cytogenetic event to clonal evolution and a potential poor prognosis.

This pediatric pathology study is not relevant to mantle cell lymphoma; it repurposes the BCL-1/Cyclin D1 IHC stain to diagnose Hirschsprung disease, a non-malignant gastrointestinal disorder.

This study evaluates the outcomes of Rituximab-Bendamustine (RB) versus the CHASER regimen as induction therapy for transplant-eligible mantle cell lymphoma, informing pre-transplant treatment selection.

Preclinical Galectin-9 induces cell death in MCL cell lines by disrupting autophagy, a novel, apoptosis-independent mechanism to potentially overcome chemoresistance.

This case report details an exceptionally rare extranodal MCL presentation in the lacrimal drainage system, emphasizing its inclusion in the differential diagnosis for masses in this location.

This case report demonstrates CNS relapse in an MCL patient with a low Ki-67 (10%), underscoring the need for CSF analysis in symptomatic patients regardless of proliferation index.

This review outlines the potential of AI-based PET/CT radiomics to improve lymphoma diagnosis and prognosis, but its specific clinical application in MCL remains undefined pending further research.

This case report describes a hyperacute, aggressive presentation of small cell, non-nodal MCL, highlighting the clinical heterogeneity and challenging prognostic assumptions for this typically indolent subtype.

This SEER database analysis confirms older age and advanced stage interact to worsen survival, while also identifying widowed marital status as an independent predictor of higher mortality in MCL.

This case report describes an MCL diagnosis in a patient with mucous membrane pemphigoid, where frontline acalabrutinib and rituximab resolved both conditions, suggesting a paraneoplastic link.

Italian experts established consensus diagnostic and therapeutic pathways for MCL, standardizing care while highlighting ongoing debates on MRD utility, immunotherapy sequencing, and CAR-T versus bispecifics.

This case report demonstrates that MCL can rarely cause membranous nephropathy, a severe renal complication that can be fully resolved by successfully treating the underlying lymphoma with chemotherapy.